About this trial
This study will explore the safety and efficacy of BASIS technology in ICAS-LVO lesions through a multicenter, prospective, registry, observational single-arm study.By registering intraoperative recanalization using this technique time, recanalization grade, operative thrombectomy times, intraoperative complications perforating branch occlusion, vascular dissection, vascular rupture, Ectopic thrombus, probability of symptomatic intracranial hemorrhage, mRS Score and mortality rate were followed up for 3 months The unique advantages of the application of the assessment BASIS in this type of lesion provide new insights into complex lesions such as ICAS-LVO The thought and operation method can shorten the operation time, improve the good prognosis, reduce the economic burden and reduce the operation Complications make a positive contribution to ensure that patients receive safe, effective and precise treatment.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age ≥18 years old;
Ischemic stroke;
Within 72 hours from the onset of symptoms to the time of visit, including post-awakening stroke or blindness For stroke patients, the time when symptoms start is defined as "the last normal time";
Neuroimaging examination indicated occlusion of anterior or posterior intracranial large vessels, TOAST type was large atherosclerosis type.
Disqualifiers
Neuroimaging findings on admission, acute occlusion of multiple vessels and tandem lesions;
History of atrial fibrillation or heart valve surgery;
There are clinical contraindications to the use of antiplatelet drugs (hemophilia or thrombocytopenia).Rare disease, known history of coagulation disorders, platelet abnormalities; There is active internal bleeding, intracranial Bleeding history, arteriovenous malformation, aneurysm, etc.);
Other types of stroke, including hemorrhagic stroke.
Trial population
ICAS-LAO stroke
Trial design
Cohort
Prospective
Treatments tested in this trial
BASIS technique
Procedure/SurgeryBalloon AngioplaSty with the dIstal protection of Stent retriever
Treatment groups
Trial outcomes
Primary outcomes
mRS scores at 90 days
functional recovery, assessed by change in modified Rankin Scale (mRS) scores (ranging from 0 \[no symptoms\] to 6 \[death\]) at 90 days after onset
FPE:first pass effect
Vascular revascularization rate by basis technique at the first attempt
Secondary outcomes
Residual stenosis rate of target vessel
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Fujian Medical University Union Hospital
Lead sponsor
Zhangzhou Municipal Hospital of Fujian Province
Collaborator
First Affiliated Hospital of Jinan University
Collaborator